Home › Compare › EFTR vs SPHD

EFTR vs SPHD: Dividend Comparison 2026

EFTR yields 1000000.00% · SPHD yields 4.00%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EFTR wins by $4.7683925249533696e+36M in total portfolio value
10 years
EFTR
EFTR
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full EFTR calculator →
SPHD
SPHD
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$899.19
Full SPHD calculator →

Portfolio growth — EFTR vs SPHD

📍 EFTR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEFTRSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EFTR + SPHD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
EFTR pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EFTR
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
SPHD
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$764.31/yr
At 15% tax rate, EFTR beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EFTR + SPHD for your $10,000?

EFTR: 50%SPHD: 50%
100% SPHD50/50100% EFTR
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EFTR right now

EFTR
Analyst Ratings
6
Buy
Consensus: Buy
Price Target
$5.50
+2749900.0% upside vs current
Range: $1.00 — $10.00
Altman Z
-13.6
Piotroski
2/9
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EFTR buys
0
SPHD buys
0
No recent congressional trades found for EFTR or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEFTRSPHD
Forward yield1000000.00% ✓4.00%
Annual dividend / share$2.00$2.00
Payout ratio50%50%
1-year div growth0%5% ✓
5-year div CAGR0%5% ✓
Portfolio after 10y$4.7683925249533696e+36M$28.0K ✓
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00 ✓$899.19
Total dividends collected$4.7683311610149396e+36M$6.4K ✓
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: EFTR vs SPHD ($10,000, DRIP)

YearEFTR PortfolioEFTR Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,120$420.00+$100.00M → EFTR
2$934,786,450,701$934,679,439,252.34$12,357$458.31+$934786.44M → EFTR
3$8,165,787,108,578,292$8,164,786,887,076,042.00$13,721$499.76+$8165787108.56M → EFTR
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$15,227$544.58+$66665884190957.63M → EFTR
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$16,885$593.02+$508662171058048128.00M → EFTR
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$18,713$645.34+$3.62723524842849e+21M → EFTR
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$20,724$701.81+$2.417368115915061e+25M → EFTR
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$22,938$762.73+$1.5056740286145463e+29M → EFTR
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$25,372$828.41+$8.764771002818475e+32M → EFTR
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$28,047$899.19+$4.7683925249533696e+36M → EFTR

EFTR vs SPHD: Complete Analysis 2026

EFTR — Stock

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.

Full EFTR Calculator →

SPHD — ETF

SPHD is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in SPHD shares.

Full SPHD Calculator →
📬

Get this EFTR vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EFTR vs SCHDEFTR vs JEPIEFTR vs OEFTR vs KOEFTR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.